Circulating tumor DNA as a noninvasive biomarker in patients with Non-Hodgkin Lymphoma (NHL)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00024180

Enrollment

200

Registered

2021-02-01

Start date

2020-09-25

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C83.3 C85

Interventions

Group 1: Non-interventional study. Determination of ctDNA in the blood of NHL patients with no effect on therapy/disease progression.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Consenting patients with histologically confirmed non-Hodgkin lymphoma.

Exclusion criteria

Exclusion criteria: Minors, nursing mothers, pregnant women, patients not capable of giving consent

Design outcomes

Primary

Measure	Time frame
Detection rate of tumor mutations in ctDNA in blood plasma at recurrence / progression.	—

Secondary

Measure	Time frame
1. quantity of ctDNA: correlation of the amount of ctDNA in blood plasma with the radiologically determined tumor burden at half and after completion of therapy. 2. PFS and OS: association of the amount of ctDNA in blood plasma at the halfway point and after the completion of therapy with PFS and OS.	—

Countries

Germany

Contacts

Public ContactFlorian Scherer

Universitätsklinikum Freiburg, Klinik für Innere Medizin I

florian.scherer@uniklinik-freiburg.de+4976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026